3D fetal software takes off

The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.

Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.

The Sonire Therapeutics ultrasound system is currently being studied for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to first-line chemotherapy.

The new ultrasound platform reportedly offers a combination of enhanced imaging and AI-enabled tools to facilitate improved workflow efficiency.

In a multicenter study of over 370 women who had surgery for ovarian cystic lesions without acute symptoms, researchers found that 42 percent of the resected lesions were deemed to have an O-RADS ultrasound risk score of 2, which has less than a one percent chance of malignancy.

With the capability of identifying possible cases of aortic value stenosis (AVS) from existing electrocardiograms (ECGs), the AI-powered screening software from AccurKardia may facilitate earlier diagnosis of AVS, which is fatally missed in 50 percent of patient who have this condition.